Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer

被引：93
作者：
Allen, LF
Eiseman, IA
Fry, DW
Lenehan, PF
机构：
[1] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Clin Dev, Ann Arbor, MI 48105 USA
[2] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Oncol, Ann Arbor, MI 48105 USA
[3] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Canc Pharmacol, Ann Arbor, MI 48105 USA
来源：
SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2003.08.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：65 / 78
页数：14
相关论文
共 108 条
[1]  
ALIMANDI M, 1995, ONCOGENE, V10, P1813
[2]   Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J].
Allen, LF ;
Lenehan, PF ;
Eiseman, IA ;
Elliott, WL ;
Fry, DW .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :11-21
[3]   The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].
Alroy, I ;
Yarden, Y .
FEBS LETTERS, 1997, 410 (01) :83-86
[4]   Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J].
Amundadottir, LT ;
Leder, P .
ONCOGENE, 1998, 16 (06) :737-746
[5]   ErbB receptor tyrosine kinase inhibitors as therapeutic agents [J].
Anderson, NG ;
Ahmad, T .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 :D1926-D1940
[6]   Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site [J].
Arteaga, CL ;
Ramsey, TT ;
Shawver, LK ;
Guyer, CA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (37) :23247-23254
[7]  
Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO
[8]  
2-8
[9]  
Baselga J, 1999, SEMIN ONCOL, V26, P78
[10]  
Baselga J, 2001, J CLIN ONCOL, V19, p41S
12345678910